Abcam, ab263413, Human UTP11L knockout HEK-293T cell lysate

Size: 1Kit
UTP11 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and Insertion of the selection cassette in exon 1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-UTP11, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
UTP11L also known as U3 small nucleolar RNA-associated protein 11-like is an RNA-binding protein with a molecular weight of approximately 80 kDa. It is expressed in various tissues but shows higher expression in brain and testis. The protein plays a mechanical role in the processing of small nucleolar RNAs where it is involved in their maturation. This RNA-binding ability enables UTP11L to participate actively in ribonucleoprotein complex formations and interact with other molecules in nucleolar compartments.
Biological function summary
UTP11L functions as an essential component of the U3 small nucleolar ribonucleoprotein (snoRNP) complex. This complex plays a pivotal role in the early cleavage steps of pre-rRNA processing an important stage in ribosome biogenesis. UTP11L facilitates the proper assembly and stabilization of this complex ensuring efficient processing of rRNA precursors into functional ribosomal RNA. These processes occur within the nucleolus the main hub for ribosome production in the cell.
Pathways
UTP11L is integral to the ribosome biogenesis and RNA processing pathways. Its interaction with the snoRNP components such as fibrillarin and NOP56 highlights its involvement in the maturation of 18S rRNA an important step for ribosomal subunit assembly. Through these pathways UTP11L aligns with other ribosomal proteins and snoRNP-associated factors playing an extensive role in maintaining the fidelity and efficiency of ribosomal function.
Studies link UTP11L to conditions such as neurodevelopmental disorders and reproductive dysfunctions. Altered expression of UTP11L or its misregulation may contribute to these pathological states by disrupting normal ribosomal assembly and function. Moreover its association with proteins like nucleolin and NOP56 in these contexts implies that changes in such interactions could impact cellular homeostasis leading to disease manifestation. Researchers continue to investigate UTP11L's role in these disorders to potentially target it for therapeutic interventions.